X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA LUPIN LTD ALEMBIC PHARMA/
LUPIN LTD
 
P/E (TTM) x 29.0 19.9 145.7% View Chart
P/BV x 6.6 2.7 245.3% View Chart
Dividend Yield % 0.7 0.9 76.6%  

Financials

 ALEMBIC PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
LUPIN LTD
Mar-17
ALEMBIC PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs7921,750 45.2%   
Low Rs4431,384 32.0%   
Sales per share (Unadj.) Rs167.0387.4 43.1%  
Earnings per share (Unadj.) Rs38.256.6 67.4%  
Cash flow per share (Unadj.) Rs42.076.8 54.7%  
Dividends per share (Unadj.) Rs4.007.50 53.3%  
Dividend yield (eoy) %0.60.5 135.4%  
Book value per share (Unadj.) Rs84.9298.9 28.4%  
Shares outstanding (eoy) m188.52451.58 41.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.74.0 91.4%   
Avg P/E ratio x16.227.7 58.5%  
P/CF ratio (eoy) x14.720.4 72.1%  
Price / Book Value ratio x7.35.2 138.7%  
Dividend payout %10.513.2 79.1%   
Avg Mkt Cap Rs m116,383707,513 16.4%   
No. of employees `000NA16.8 0.0%   
Total wages/salary Rs m4,21428,495 14.8%   
Avg. sales/employee Rs ThNM10,418.3-  
Avg. wages/employee Rs ThNM1,697.0-  
Avg. net profit/employee Rs ThNM1,523.0-  
INCOME DATA
Net Sales Rs m31,487174,943 18.0%  
Other income Rs m551,065 5.2%   
Total revenues Rs m31,542176,008 17.9%   
Gross profit Rs m10,06044,931 22.4%  
Depreciation Rs m7229,122 7.9%   
Interest Rs m371,525 2.4%   
Profit before tax Rs m9,35635,349 26.5%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m-283 -1.8%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1609,785 22.1%   
Profit after tax Rs m7,19425,575 28.1%  
Gross profit margin %31.925.7 124.4%  
Effective tax rate %23.127.7 83.4%   
Net profit margin %22.814.6 156.3%  
BALANCE SHEET DATA
Current assets Rs m15,066119,542 12.6%   
Current liabilities Rs m7,67461,206 12.5%   
Net working cap to sales %23.533.3 70.4%  
Current ratio x2.02.0 100.5%  
Inventory Days Days6776 88.1%  
Debtors Days Days4190 45.2%  
Net fixed assets Rs m8,237131,660 6.3%   
Share capital Rs m377903 41.7%   
"Free" reserves Rs m15,416134,073 11.5%   
Net worth Rs m16,005134,976 11.9%   
Long term debt Rs m056,478 0.0%   
Total assets Rs m24,594266,073 9.2%  
Interest coverage x255.224.2 1,055.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.7 194.7%   
Return on assets %29.410.2 288.7%  
Return on equity %44.918.9 237.2%  
Return on capital %58.719.3 304.6%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81181,885 21.8%   
Fx outflow Rs m5,31821,506 24.7%   
Net fx Rs m12,49360,378 20.7%   
CASH FLOW
From Operations Rs m9,30441,148 22.6%  
From Investments Rs m-3,105-25,287 12.3%  
From Financial Activity Rs m-1,9594,332 -45.2%  
Net Cashflow Rs m4,24020,193 21.0%  

Share Holding

Indian Promoters % 74.1 46.6 159.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 31.9 28.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.1 137.6%  
Shareholders   49,328 98,259 50.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   CIPLA  PFIZER  DR. DATSONS LABS  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS